옵션 체인은 다양한 행사가격과 만기일에 대한 Galapagos의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Galapagos에 대한 시장 심리를 평가합니다..

Galapagos (NASDAQ:GLPG) 주식, 옵션 체인

Galapagos

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Analyst Color

Biotech

News

Downgrades

Health Care

General

GILD

GLPG

뱅크 오브 아메리카 증권(BofA)은 유럽 제약회사 갈라파고스 NV(NASDAQ:GLPG)을 하향 조정하며, 단기적인 촉매제 부족에 대해 언급했다.갈라파고스의 기업 가치는 지속적으로 낮은 15억 ~ 20억 달러 사이에서 유지되고 있으며, 이에 대해 애널리스트들은 즉각적이거나 중기적인 해결책을 기대하지 않고 있다.게다가 이 회사의 주요 프로그램은 차별화가 불분명하고 성장을 촉진할 중요한 촉매제가 부족한 혼잡한 시장에 진출하고 있다.

느린 파이프라인 진전으로 어려운 싸움을 하는 갈라파고스 평가 하향: 분석가

Galapagos NV - American Depositary Shares

Galapagos NV

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling by more than 300 points on Friday.
The Dow traded down 0.78% to 43,410.32 while the NASDAQ fell 2.50% to 18,630.37. The S&amp;P 500 also fell, dropping, 1.51% to 5,859.61.
Check This Out: <a href="https://www.benzinga.com/24/11/42005109/top-4-utilities-stocks-that-may-keep-you-up-at-night-this-quarter">Top 4 Utilities Stocks That May Keep You Up At Night This Quarter</a>
Leading and Lagging Sectors Utilities shares rose by 1% on Friday.
In trading on Friday, information technology shares fell by 2.7%.
Top Headline
The total number of active U.S. oil rigs fell by one to 478 rigs this week, Baker Hughes Inc reported.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>The Arena Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AREN#NYSE">AREN</a>) shares shot up 181% to $1.63 after it announced its first ever profitable quarter.</li>
<li>Shares of Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) got a boost, surging 55% to $20.59 after the energy company became the latest to announce a major deal to power AI data centers. Bloom Energy announced Thursday evening that it has signed a supply agreement with American Electric Power Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) for up to 1 gigawatt (GW) of its products, the largest commercial procurement of fuel cells in the world to date.&nbsp;</li>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) shares were also up, gaining 46% to $1.29 after the company announced a $400,000 contract to supply autonomous cleaning robots at Singapore&#8217;s International Airport Terminal.</li>
</ul>
Equities Trading DOWN
<ul>
<li>TFF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares dropped 77% to $0.37 after the company announced it will wind down its operations.</li>
<li>Shares of Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) were down 70% to $0.10 after the company announced that its CHAPERONE trial is not meeting its primary endpoint, prompting the discontinuation of the study and a review of the full data set to evaluate next steps for the program.</li>
<li>Ryvyl Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) was down, falling 26% to $1.26 after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance.</li>
</ul>
Commodities In commodity news, oil traded down 2.2% to $67.20 while gold traded down 0.1% at $2,572.20.
Silver traded down 0.5% to $30.425 on Friday, while copper fell 0.5% to $4.0690.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.77%, Germany's DAX fell 0.27% and France's CAC 40 fell 0.58%. Spain's IBEX 35 Index gained 0.97%, while London's FTSE 100 fell 0.09%.
The annual inflation rate in Italy increased to 0.9% in October versus 0.7% in the prior month, while France&#8217;s annual inflation rate rose to 1.2% in October. The GDP in the UK grew by 1% year-over-year during the third quarter.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 gaining 0.28%, Hong Kong's Hang Seng Index falling 0.05% and China's Shanghai Composite Index dipping 1.45%.
Hong Kong's economy expanded by 1.8% year-over-year in the third quarter compared to a 3.2% increase in the previous period. China&#8217;s retail sales rose by 4.8% year-over-year in October, while industrial production rose by 5.3% year-over-year in October.
Economics
<ul>
<li>The NY Empire State Manufacturing Index surged to 31.2 in November versus -11.9 in the previous month and topping market estimates of -0.7.</li>
<li>U.S. export prices increased by 0.8% in October, while import prices rose by 0.3% month-over-month in October.</li>
<li>U.S. retail sales rose 0.4% month-over-month in October compared to a revised 0.8% increase in September, and toping market estimates of 0.3%.</li>
<li>U.S. industrial production declined by 0.3% in October compared to a revised 0.5% declined in September.</li>
<li>The total number of active U.S. oil rigs fell by one to 478 rigs this week, Baker Hughes Inc reported.</li>
<li>U.S. business inventories rose 0.1% month-over-month in September compared to a 0.3% gain in August and versus market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42007351/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks With Over 7% Dividend Yields</a></li>
</ul>

Earnings

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AREN

EYEN

RVYL

SPPL

TFFP

Crude Oil Dips Over 2%; Bloom Energy Shares Spike Higher

Needham analyst Mike Matson reiterates Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Buy and maintains $112 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Haemonetics, Maintains $112 Price Target

Macro Economic Events

Economics

Federal Reserve

Fed's Goolsbee Says Neutral Is Significantly Lower Than Where Fed Policy Rate Is Now; If Productivity Growth Stays Higher Than Trend, Need To Be Careful Relying On GDP Growth Rate To Check If Economy Is Overheating

<ul>
<li>Postal Service continues to offer a great value for shipping with our reliable service to the American people. &nbsp;</li>
<li>Pricing actions part of balanced approach under "Delivering for America," the Postal Service's 10-year plan for achieving financial sustainability and service excellence.</li>
<li>Rate changes will support the $40 billion of investments in people, technology, and infrastructure and continue the modernization and improvement of the Postal Service's operations and customer experience.</li>
<li>As we previously announced, the Postal Service will not be <a href="https://www.streetinsider.com/entities/Raising+Prices">raising prices</a> in January for our Mailing Services, therefore, the price of a First-Class stamp will remain unchanged.</li>
</ul>
WASHINGTON, Nov. 15, 2024 /PRNewswire/ -- Today, the Postal Service filed notice with the Postal Regulatory Commission (PRC) for Shipping Services price changes to take effect January 19, 2025. The proposed adjustments were approved by the Governors of the USPS this week.&nbsp;
The change would raise Shipping Services prices approximately 3.2 percent for Priority Mail service and Priority Mail Express service, 3.9 percent for USPS Ground Advantage and 9.2 percent for Parcel Select.
Although Mailing Services price increases are based on the consumer price index, Shipping Services prices are primarily adjusted according to market conditions. The governors believe these new rates will keep the Postal Service competitive while providing the agency with needed revenue. As we previously announced, the Postal Service will not be raising prices in January for our Mailing Services.
As a strategic part of the <a href="https://about.usps.com/what/strategic-plans/delivering-for-america/?_gl=1&#x2A;63lmng&#x2A;_ga&#x2A;MTU2OTA3OTA5MC4xNjU2NTIwNTUx&#x2A;_ga_3NXP3C8S9V&#x2A;MTY2NDk4ODA1NS40NDIuMS4xNjY0OTg4MDkyLjAuMC4w">Delivering for America</a> 10-year plan, these proposed changes will support the Postal Service in creating a revitalized organization capable of achieving our public service mission — providing a nationwide, integrated network for the delivery of mail and packages at least six days a week — in a cost-effective and financially sustainable manner over the long term, just as the U.S. Congress has intended.&nbsp;
The PRC will review the changes before they are scheduled to take effect. The complete Postal Service price filing, with prices for all products, can be found on the PRC website under the Daily Listings section at <a href="https://prc.arkcase.com/portal/docket-search/daily-listings">prc.gov/dockets/daily</a>. The Mailing Services filing is Docket No. CP2025-1. The price tables are also available on the Postal Service's Postal Explorer website at <a href="https://pe.usps.com/PriceChange/Index">pe.usps.com/PriceChange/Index</a>.

U.S. Postal Service Recommends New Competitive Prices For 2025; Will Not Be Raising Prices In Jan For Mailing Services; Price Of First-Class Stamp To Remain Unchanged; Change Would Raise Shipping Services Prices About 3.2% For Priority Mail Service And Priority Mail Express Service; Change Would Raise Shipping Services Prices 3.9% For USPS Ground Advantage & 9.2% For Parcel Select

Needham analyst Mayank Tandon maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Buy and raises the price target from $245 to $265.

GLOB

Needham Maintains Buy on Globant, Raises Price Target to $265

WIIM

HALO

Halozyme Therapeutics shares are trading lower after the company announced a proposal to combine with Evotec.

HC Wainwright &amp; Co. analyst Edward White reiterates InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) with a Buy and maintains $8 price target.

IFRX

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

Bancorp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NYSE">TBBK</a>) short percent of float has fallen 3.81% since its last report. The company recently reported that it has 6.48 million shares sold short, which is 17.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.33 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Bancorp Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731698129_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bancorp has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Bancorp's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Bancorp's peer group average for short interest as a percentage of float is 4.18%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

TBBK

How Is The Market Feeling About Bancorp?

SPS Commerce's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NYSE">SPSC</a>) short percent of float has risen 3.94% since its last report. The company recently reported that it has 719 thousand shares sold short, which is 2.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>SPS Commerce Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731698124_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SPS Commerce has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing SPS Commerce's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SPS Commerce's peer group average for short interest as a percentage of float is 8.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SPSC

Looking Into SPS Commerce's Recent Short Interest

Monday.Com's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NYSE">MNDY</a>) short percent of float has risen 4.31% since its last report. The company recently reported that it has 2.71 million shares sold short, which is 6.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Monday.Com Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731698119_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Monday.Com has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Monday.Com's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Monday.Com's peer group average for short interest as a percentage of float is 4.93%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MNDY

Looking Into Monday.Com's Recent Short Interest

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and maintains $4 price target.

ATNM

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target

On Friday, Gilead Sciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42012386/gileads-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety-profile-in-mana" rel="noreferrer noopener">efficacy and safety of Livdelzi</a>.
The study showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi&nbsp;(seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression.
Additionally, 41% (15 out of 37) of participants achieved normalization of alkaline phosphatase (ALP) levels, a critical biomarker of liver function.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost" rel="noreferrer noopener">HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook</a>
Livdelzi continues to appear generally well tolerated, with no new safety signals or change in frequency of adverse events (AEs) with up to three years of exposure.
In August, the FDA granted accelerated approval for&nbsp;Gilead&#8217;s Livdelzi&nbsp;for primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA or as monotherapy in patients&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal" rel="noreferrer noopener">unable to tolerate UDCA</a>.
In addition to the ASSURE data, Gilead showcased findings from two oral presentations highlighting additional analyses from the Phase 3 RESPONSE trial:
<ul>
<li>At Month 12, the adjusted mean change from baseline in ALP for participants with cirrhosis on Livdelzi was -121.4 U/L (a decrease of approximately 35% from baseline) versus 23.2 U/L (an increase of approximately 6.6%) on placebo.</li>
<li>-134.8 U/L (down 43.5%) for Livdelzi versus -18.0 U/L (a decrease of approximately 5.8%) for placebo in participants without cirrhosis.</li>
<li>A secondary analysis of pruritus in RESPONSE showed that among participants with a numerical rating score (NRS) of ≥4 and NRS ≥7 at baseline, Livdelzi led to near resolution (NRS of 0 or 1) of itch at Month 12 in 26.5% and 18.8% of participants, respectively, versus 0% of participants on placebo.</li>
</ul>
Price Action: GILD stock is down 3.48% at $88.90 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/bonds/24/11/42003337/trumps-victory-spurs-50b-corporate-bond-surge-as-tax-cut-optimism-drives-borrowing-costs-to-25-year-low" target="_blank" rel="noreferrer noopener">Trump&#8217;s Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low</a></li>
</ul>

Equities

Large Cap

Movers

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

Wells Fargo analyst Ike Boruchow maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Overweight and raises the price target from $65 to $75.

Wells Fargo Maintains Overweight on Tapestry, Raises Price Target to $75

HC Wainwright &amp; Co. analyst Robert Burns reiterates Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Buy and maintains $22 price target.

YMAB

HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $22 Price Target

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) with a Overweight and lowers the price target from $20 to $12.

CABA

Wells Fargo Maintains Overweight on Cabaletta Bio, Lowers Price Target to $12

The recent U.S. presidential election results, including a Republican sweep, have raised questions about the future of renewable energy under President-elect Donald Trump&#8217;s leadership.
Morgan Stanley&#8217;s report evaluates the economic impact on renewables under various policy scenarios and its effects on earnings.
The analyst has adjusted its view on the clean tech industry to &#8220;In-Line&#8221; from &#8220;Attractive.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41880110/solar-renewables-stocks-crash-after-trump-win-should-you-buy-now-at-cheap-valuations" rel="noreferrer noopener">Solar, Renewables Stocks Crash After Trump Win: Should You Buy Now At Cheap Valuations?</a>
While long-term demand for renewables is likely stronger than current market perceptions, near-term growth prospects have become less clear due to new uncertainties.
It&#8217;s important to remember that these new uncertainties add to the already difficult environment facing the clean energy sector, dealing with issues such as permitting and interconnection delays, funding challenges, and intense competition that have hurt profitability.
Uncertainty about the Inflation Reduction Act (IRA), tariffs, and interest rates has significantly impacted clean fuel valuations.
Morgan Stanley writes that clear guidance on the IRA is essential for clean tech valuations to rebound. However, this may take time since it will likely be linked to discussions about the Tax Cuts and Job Act&nbsp;(TCJA), which is set to expire at the end of 2025.
Morgan Stanley recommends investing in stocks with high-quality and durable growth/ margins, with a clear catalyst path and/or strong balance sheet to weather any near-term volatility in growth and/or profitability.
<ul>
<li>The analyst maintains an Overweight rating on GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), and Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>).</li>
</ul>
However, the analyst has downgraded three cleantech stocks from Equal-weight to Underweight, including:
<ul>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>): The analyst reduced the price target from $23 to $9, citing slower profitability due to decreased European demand and tough competition from cheaper Chinese manufacturers. As a result, the company is not expected to break even on <a href="https://www.benzinga.com/quote/SEDG/analyst-ratings" target="_blank" rel="noreferrer noopener">EBITDA until after 2026</a>. At last check Friday, the stock was trading 13.2% lower at $11.13.</li>
<li>Maxeon Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>): Morgan Stanley anticipates a slow recovery to profitability due to increasing competition in Europe&#8217;s utility-scale solar market, which will likely keep pushing prices down. The analyst maintains the <a href="https://www.benzinga.com/quote/MAXN/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $4</a>. Additionally, recent customer losses in the U.S. residential market could make maintaining market share and premium pricing harder. Stock is trading 10.08% lower at $10.08 at last check Friday.</li>
<li>TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>): The analyst notes an uncertainty about how quickly the U.S. wind market will recover, mainly due to challenges in securing financing and recent issues with design and inspections as the industry shifts to larger blade sizes. Morgan Stanley has cut the <a href="https://www.benzinga.com/quote/TPIC/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $4 to $2</a>. Stock is down 8.82% at $2.16 at the last check Friday.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42012689/life-insurance-firm-aegon-trades-higher-as-capital-ratios-remain-solid" target="_blank" rel="noreferrer noopener">Life Insurance Firm Aegon Trades Higher As Capital Ratios&#8217; Remain Solid&#8217;</a></li>
</ul>
Photo via Shutterstock

Government

FSLR

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

SEDG

TPIC

Trump's Win, Economic Challenges Lead to Tougher Outlook for Renewable Energy Stocks: Morgan Stanley

Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) with a Overweight and lowers the price target from $44 to $24.

KYTX

Wells Fargo Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $24

Wells Fargo analyst Roger Read maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and raises the price target from $32 to $35.

CTRA

Wells Fargo Maintains Overweight on Coterra Energy, Raises Price Target to $35

Guggenheim analyst Michael Schmidt maintains Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) with a Buy and lowers the price target from $12 to $8.

ZNTL

Guggenheim Maintains Buy on Zentalis Pharma, Lowers Price Target to $8

Fed's Goolsbee Says Everything Is Always On The Fed Policy Table; Inflation Numbers Have To Keep Improving; If Started To See Reversal On Inflation Progress, Would Have To Figure Out If It Is A Bump; Not A Lot Has Changed On That In Last Couple Weeks; Recent Inflation Has Been A Little Higher Than Target, If That Is Extended, It's Too High; There's A Lot Of Volatility On Inflation Data Series

Total net revenues for the nine months ended September 30, amounted to EUR 200.1M, compared to EUR 179.8 M for the nine months ended September 30, ...

Galapagos:1st nine months FY24 net income EUR 103.5 vs. EUR 90.3 last year

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Galapagos (GLPG – Research Report). The company's shares opened to...

Galapagos (GLPG) Receives a Buy from TD Cowen

Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript

Galapagos NV 2024 Q3 - Results - Earnings Call Presentation

Galapagos NV ( ($GLPG) ) has released its Q3 earnings. Here is a breakdown of the information Galapagos NV presented to its investors. Galapagos NV...

Galapagos NV Sees Pipeline Growth Amid Financial Challenges

In a report released today, Emily Field from Barclays maintained a Hold rating on Galapagos (0JXZ – Research Report), with a price target of €30.00...

Barclays Keeps Their Hold Rating on Galapagos (0JXZ)

Jason Gerberry, an analyst from Bank of America Securities, reiterated the Sell rating on Galapagos (GLPG – Research Report). The associated price ...

Cautious Outlook for Galapagos: Sell Rating Amid Pipeline Uncertainties and Competitive Pressures

Deutsche Bank analyst Emmanuel Papadakis lowered the firm's price target on Galapagos (GLPG) to EUR 28 from EUR 30 and keeps a Hold rating on the s...

Galapagos price target lowered to EUR 28 from EUR 30 at Deutsche Bank

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Haleon PLC Sponsored ADR (HLN – Research Report), Insmed (INSM – ...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)

Galapagos (GLPG) announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66th American Society of Hematology...

Galapagos to present data on CAR T-cell therapy candidates GLPG5101 and GLPG5201

GLPGF

INSM

Press Releases

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Galapagos receives transparency notification from FMR LLC

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Galapagos receives transparency notification from EcoR1 Capital

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Comments

Galapagos

Galapagos (GLPG) 옵션

Galapagos (NASDAQ:GLPG) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌